LT2892535T - Adjuvantinis vėžio gydymo būdas - Google Patents

Adjuvantinis vėžio gydymo būdas

Info

Publication number
LT2892535T
LT2892535T LTEPPCT/US2013/057432T LT13057432T LT2892535T LT 2892535 T LT2892535 T LT 2892535T LT 13057432 T LT13057432 T LT 13057432T LT 2892535 T LT2892535 T LT 2892535T
Authority
LT
Lithuania
Prior art keywords
cancer
adjuvant treatment
adjuvant
treatment
Prior art date
Application number
LTEPPCT/US2013/057432T
Other languages
English (en)
Lithuanian (lt)
Inventor
Sylvie Laquerre
Peter F. Lebowitz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50237545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2892535(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT2892535T publication Critical patent/LT2892535T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEPPCT/US2013/057432T 2012-09-04 2013-08-30 Adjuvantinis vėžio gydymo būdas LT2892535T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261696375P 2012-09-04 2012-09-04
PCT/US2013/057432 WO2014039375A1 (en) 2012-09-04 2013-08-30 Method of adjuvant cancer treatment

Publications (1)

Publication Number Publication Date
LT2892535T true LT2892535T (lt) 2021-12-10

Family

ID=50237545

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2013/057432T LT2892535T (lt) 2012-09-04 2013-08-30 Adjuvantinis vėžio gydymo būdas

Country Status (20)

Country Link
US (7) US20150216868A1 (enExample)
EP (2) EP2892535B1 (enExample)
JP (3) JP2015527374A (enExample)
KR (1) KR102134585B1 (enExample)
CN (2) CN104582706A (enExample)
AU (2) AU2013313050A1 (enExample)
BR (1) BR112015004578A2 (enExample)
CA (1) CA2882437C (enExample)
CY (1) CY1124812T1 (enExample)
DK (1) DK2892535T3 (enExample)
ES (1) ES2900825T3 (enExample)
HR (1) HRP20211817T1 (enExample)
HU (1) HUE056646T2 (enExample)
IN (1) IN2015KN00449A (enExample)
LT (1) LT2892535T (enExample)
PL (1) PL2892535T3 (enExample)
PT (1) PT2892535T (enExample)
RU (1) RU2640180C2 (enExample)
SI (1) SI2892535T1 (enExample)
WO (1) WO2014039375A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104582706A (zh) 2012-09-04 2015-04-29 葛兰素史克有限责任公司 辅助癌症治疗的方法
CN111534580B (zh) 2013-12-28 2024-06-04 夸登特健康公司 用于检测遗传变异的方法和系统
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
WO2018203219A1 (en) * 2017-05-02 2018-11-08 Novartis Ag Combination therapy
US11890286B2 (en) * 2018-04-17 2024-02-06 The University Of Chicago Methods and compositions for treating cancer
CN109106893B (zh) * 2018-11-12 2021-04-20 上海市中西医结合医院 一种调节肠道屏障功能的中药复方制剂及其制备方法
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
CN114981298B (zh) * 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
US20250032494A1 (en) 2021-12-06 2025-01-30 My Personal Therapeutics Ltd A combination treatment for cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100883289B1 (ko) * 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
CN103169729A (zh) * 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
HUE060206T2 (hu) * 2009-10-16 2023-02-28 Novartis Ag MEK gátlót és B-Raf gátlót tartalmazó kombináció
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
CN104582706A (zh) 2012-09-04 2015-04-29 葛兰素史克有限责任公司 辅助癌症治疗的方法

Also Published As

Publication number Publication date
PL2892535T3 (pl) 2022-01-31
JP2015527374A (ja) 2015-09-17
CA2882437A1 (en) 2014-03-13
US20180338979A1 (en) 2018-11-29
JP6684941B2 (ja) 2020-04-22
IN2015KN00449A (enExample) 2015-07-17
CA2882437C (en) 2021-03-02
US20200054641A1 (en) 2020-02-20
EP2892535A1 (en) 2015-07-15
PT2892535T (pt) 2021-12-15
JP6511117B2 (ja) 2019-05-15
US20170202842A1 (en) 2017-07-20
JP2019142899A (ja) 2019-08-29
ES2900825T3 (es) 2022-03-18
AU2016244279B2 (en) 2018-01-04
HK1206642A1 (en) 2016-01-15
RU2015105821A (ru) 2016-10-20
BR112015004578A2 (pt) 2017-07-04
US20210060021A1 (en) 2021-03-04
CY1124812T1 (el) 2022-11-25
US20260207608A1 (en) 2026-07-23
EP2892535B1 (en) 2021-09-22
WO2014039375A1 (en) 2014-03-13
RU2640180C2 (ru) 2017-12-26
HRP20211817T1 (hr) 2022-03-04
US20150216868A1 (en) 2015-08-06
EP2892535A4 (en) 2016-04-13
AU2013313050A1 (en) 2015-03-26
DK2892535T3 (da) 2022-01-03
HUE056646T2 (hu) 2022-02-28
KR20150047619A (ko) 2015-05-04
KR102134585B1 (ko) 2020-07-17
SI2892535T1 (sl) 2022-01-31
CN107308164A (zh) 2017-11-03
CN104582706A (zh) 2015-04-29
JP2018058859A (ja) 2018-04-12
US20230330091A1 (en) 2023-10-19
AU2016244279A1 (en) 2016-11-03
EP3981408A1 (en) 2022-04-13
US10869869B2 (en) 2020-12-22

Similar Documents

Publication Publication Date Title
IL288181A (en) Cancer treatment methods
IL237791B (en) A method for treating cancer
SG11201503893RA (en) Method of treating cancer
SG11201501653RA (en) Methods for the treatment of locally advanced breast cancer
IL232890A0 (en) Immunogenic therapy for cancer
IL232530A0 (en) Combined cancer treatment
EP2895206A4 (en) METHOD FOR TREATING CARCINOMA
IL228430A0 (en) Cancer treatment
PL2892535T3 (pl) Sposób leczenia adjuwantowego raka
EP2903644A4 (en) TREATMENT OF CANCER
GB201217892D0 (en) Treatment of cancer
IL237229A0 (en) Methods of treating cancer using lipoplatin
GB201217890D0 (en) Treatment of cancer
IL232266A0 (en) Cancer treatment methods
GB201208296D0 (en) Treatment of cancer
GB201121783D0 (en) Treatment of cancer
GB201221032D0 (en) Method of treatment
GB201207894D0 (en) Method of treatment
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
AU2012905667A0 (en) Vaccines for treatment of cancer
GB201206330D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment